Form 4: PROCEPT BioRobotics Director Sells Over 75,000 Shares Under Pre-Arranged Trading Plan, Acquires New Equity Awards

A director at PROCEPT BioRobotics Corp, Antal Rohit Desai, reported the sale of 75,000 shares of common stock through a Rule 10b5-1 trading plan, while also acquiring new restricted stock units and stock options.

Summary

• Antal Rohit Desai, a Director of PROCEPT BioRobotics Corp (PRCT), reported multiple transactions involving the company's common stock and derivative securities.
• Between June 10, 2025, and June 12, 2025, Mr. Desai sold a total of 75,000 shares of common stock.
• These sales were executed at weighted average prices ranging from $61.2783 to $64.6728 per share.
• All reported sales were conducted pursuant to a pre-arranged Rule 10b5-1 Trading Plan, which was adopted by Mr. Desai on November 5, 2024.
• A significant portion of the sold shares (60,600 shares) were indirectly owned through 'The 2:22 DNA Trust'.
• On June 10, 2025, Mr. Desai acquired 1,538 restricted stock units (RSUs) at a price of $0, representing a contingent right to receive one share of Common Stock per RSU.
• Also on June 10, 2025, Mr. Desai acquired 2,771 stock options (right to buy) with an exercise price of $64.23.
• Following these transactions, Mr. Desai directly beneficially owns 8,403 shares of common stock and 2,771 stock options.
• Indirect beneficial ownership through 'The 2:22 DNA Trust' stands at 14,363 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are significant sales by a director, they were conducted under a pre-arranged 10b5-1 plan, which mitigates the negative perception often associated with insider selling. Furthermore, the director also acquired new equity awards (RSUs and stock options), indicating continued alignment with the company's future.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled disposition rather than a reaction to immediate company performance, which can reduce negative market interpretation.
• The acquisition of 1,538 Restricted Stock Units (RSUs) and 2,771 Stock Options demonstrates continued equity alignment and incentive for the director with the company's long-term performance, as these awards vest subject to continued service.

Negatives

• A director selling a substantial number of shares (75,000 shares) could be perceived negatively by some investors, potentially signaling a lack of confidence, even if pre-planned.
• The sales occurred across a range of prices, with some transactions at lower weighted average prices (e.g., $61.2783), which might suggest a desire to liquidate holdings regardless of minor price fluctuations.

Risks

• While the sales were pre-planned, significant insider selling can sometimes lead to negative market sentiment or speculation, potentially impacting the company's stock price.
• The vesting of RSUs and stock options is subject to continued service, meaning the director must remain with the company to fully realize these benefits.

Future Outlook

The acquired restricted stock units and stock options are set to vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, contingent upon the director's continued service.

Management Comments

• "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 5, 2024."
• "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."

Industry Context

This Form 4 filing details insider trading activity specific to PROCEPT BioRobotics Corp. While not directly indicative of broader industry trends, insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects within its sector.

Corporate Governance

Related Party Transactions

• A significant portion of the shares sold (60,600 shares) were indirectly owned by the reporting person through 'The 2:22 DNA Trust', which is considered a related party transaction.

Stakeholder Impact

• Shareholders: May observe the director's selling activity, which could influence their perception of the stock, though the 10b5-1 plan provides context.
• Employees: The director's continued equity awards (RSUs and options) suggest ongoing commitment, which can be positive for employee morale and stability.

Next Steps

• Vesting of 1,538 Restricted Stock Units (RSUs) on the earlier of June 10, 2026, or the date of the next annual meeting following the grant date, subject to continued service.
• Vesting of 2,771 Stock Options on the earlier of June 10, 2026, or the date of the next annual meeting following the grant date, subject to continued service.

Key Dates

Recommendation

Keywords

PROCEPT BioRobotics, PRCT, Form 4, Insider Trading, Stock Sales, Director, Rule 10b5-1 Plan, Restricted Stock Units, Stock Options, Beneficial Ownership